Future’s Best of Show at NAB 2025 awards have been announced. The annual awards celebrate products being launched or on ...

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus ...

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 ...

Improvado Helps Customers Drive Seamless Marketing Data Integration and Advanced Analytics. SAN DIEGO, CALIFORNIA / / March 27, 2025 / Improvado, a leading AI-powe ...

Vision Marine Technologies Inc. (NASDAQ:VMAR), a pioneer in electric marine propulsion, today announced that the Company’s board of directors (the “Board”) approved a 10 -for-1 reverse stock split of ...

Jaguar Health (JAGX) announced that the FDA has granted Napo a Type C Meeting in the second quarter to discuss the responder analysis in the ...

Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has granted Napo a Type C Meeting in the second quarter of 2025 to ...

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified ...

As announced, the analysis of the prespecified subgroup of adult patients with breast cancer from the Company's recently conducted Phase 3 prophylactic OnTarget clinical trial for diarrhea in ...